Renascience

Renascience EBIT Margin

The EBIT Margin (Operating Margin) of Renascience (4889.T) as of Nov 19, 2026 is -520.59 %. In the previous year, EBIT Margin (Operating Margin) was -134.77 % — a change of 286.29% (lower).

EBIT Margin

-520.59 %

YoY

286.29%

Last updated:

EBIT Margin (Operating Margin) of Renascience is 2026 -520.59 % . EBIT Margin (Operating Margin) of Renascience was 2025 -134.77 % . It decreases by 286.29% lower compared to the previous year.

For Renascience, the operating (EBIT) margin of -520.6% is down versus -204.7% a few years ago.

The Renascience EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2020
-254.17 JPY
Jan 1, 2021
-41.05 JPY
Jan 1, 2022
-151.32 JPY
Jan 1, 2023
-332.06 JPY
Jan 1, 2024
-129.96 JPY
Jan 1, 2025
-134.77 JPY
Jan 1, 2026
-520.59 JPY
The Renascience EBIT Margin history
YEAREBIT MarginYoY
-520.59 %+286.29%
-134.77 %+3.70%
-129.96 %-60.86%
-332.06 %+119.44%
-151.32 %+268.62%
-41.05 %-83.85%
-254.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

EBIT Margin (Operating Margin) of Renascience is -520.59 % in 2026.

EBIT Margin (Operating Margin) of Renascience changed from -134.77 % to -520.59 %, representing a 286.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Renascience since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Renascience

All Key Metrics — Renascience